Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) EBIT Margin (2022 - 2025)

Historic EBIT Margin for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Q1 2025 value amounting to 205.18%.

  • Centessa Pharmaceuticals' EBIT Margin changed N/A to 205.18% in Q1 2025 from the same period last year, while for Sep 2025 it was 1425.33%, marking a year-over-year decrease of 77153300.0%. This contributed to the annual value of 2499.39% for FY2023, which is N/A changed from last year.
  • Centessa Pharmaceuticals' EBIT Margin amounted to 205.18% in Q1 2025.
  • Centessa Pharmaceuticals' EBIT Margin's 5-year high stood at 4138.78% during Q2 2022, with a 5-year trough of 205.18% in Q1 2025.
  • Over the past 3 years, Centessa Pharmaceuticals' median EBIT Margin value was 1919.14% (recorded in 2023), while the average stood at 2097.27%.
  • Within the past 5 years, the most significant YoY rise in Centessa Pharmaceuticals' EBIT Margin was -5196800bps (2023), while the steepest drop was -22196400bps (2023).
  • Quarter analysis of 3 years shows Centessa Pharmaceuticals' EBIT Margin stood at 1888.47% in 2022, then decreased by -28bps to 1368.79% in 2023, then plummeted by -115bps to 205.18% in 2025.
  • Its EBIT Margin stands at 205.18% for Q1 2025, versus 1368.79% for Q4 2023 and 1582.41% for Q3 2023.